FLT3基因简介. FLT3基因是Ⅲ型受体酪氨酸激酶(ReceptorTyrosine Kinase，RTK)家族成员的原癌基因，其表达的蛋白结构包括5个免疫球蛋白（Ig）样结构域组成的胞外区，1个跨膜区，1个近膜区（JM），以及胞内由激酶插入区分隔而成的两个酪氨酸激酶（TK）区。

2021年5月24日 · We investigated the combination of FLT3 TKIs (Gilteritinib or Sorafenib), with Venetoclax, a BCL-2 selective inhibitor (BCL-2i), on FLT3/ITD leukemia cells. The combination of a FLT3 TKI and a BCL-2i synergistically reduced cell proliferation and enhanced apoptosis/cell death in FLT3/ITD cell lines and primary AML samples.

2021年5月30日 · FLT3-mutated acute myeloid leukemia accounts for around 30% of acute myeloid leukemia (AML). The mutation carried a poor prognosis until the rise of tyrosine kinase inhibitors (TKIs). New potent and specific inhibitors have successfully altered the course of the disease, increasing the complete resp …

FLT3 is a member of the class III receptor tyrosine kinase family that exerts a key role in the proliferation and differentiation of hematopoietic progenitor cells. Around 30% of newly diagnosed AML patients carry a genetic modification in the FLT3 gene [5].

2024年11月5日 · We investigated the clinical activity, PK, safety and resistance mechanisms of single-agent PHI-101 in patients (pts) with refractory/relapsed acute myeloid leukemia (R/R AML) with FLT3-ITD mutations.(NCT04842370)

2024年12月20日 · 联合强化疗的TKI选择. 对于fit新诊断FLT3 mut+ AML患者，标准一线强化疗方案包括阿糖腺苷和蒽环类药物（7+3）联合 FLT3 抑制剂，每个诱导周期持续 14 天；美国已有两种药物获批：quizartinib（用于 FLT3-ITD 突变）或midostaurin（用于 FLT3-ITD 或 FLT3-TKD 突 …

2024年9月16日 · We first examined whether YPN-005 exerted synergistic antileukemic effects with FLT3-TKIs in AML cell lines harboring FLT3 -ITD mutation. FLT3 -ITD-mutated AML cells were treated with YPN-005...

2021年5月24日 · We investigated the combination of FLT3 TKIs (Gilteritinib or Sorafenib), with Venetoclax, a BCL-2 selective inhibitor (BCL-2i), on FLT3/ITD leukemia cells. The combination of a FLT3 TKI and...

Treatment with FLT3 tyrosine kinase inhibitors. Activation of signaling pathways via RTKs plays a central role in the pathogenesis of AML, and inhibition of these tyrosine kinases using small molecules represents an attractive therapeutic concept. One option to interfere with FLT3 activity is to inhibit its kinase activity.

2024年5月29日 · FLT3 tyrosine kinase inhibitors (TKIs) alone have limited and transient clinical efficacy thus calling for new targets for more effective combination therapy. In a loss-of-function RNAi screen,...